We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+14.39%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.85B
AUM Growth
+$177M
Cap. Flow
-$53.9M
Cap. Flow %
-1.89%
Top 10 Hldgs %
28.19%
Holding
216
New
12
Increased
42
Reduced
44
Closed
16

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$46M
2
DHR icon
Danaher
DHR
+$34.4M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$30.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$22.3M
5
DXCM icon
DexCom
DXCM
+$20M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$44.2M
2
MRK icon
Merck
MRK
+$39.7M
3
PFE icon
Pfizer
PFE
+$39.7M
4
ABBV icon
AbbVie
ABBV
+$24.5M
5
CNC icon
Centene
CNC
+$23.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.34%
2 Real Estate 2.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
51
Ascendis Pharma A/S
ASND
$15.9B
$16.1M 0.56%
96,246
-29,500
-23% -$4.88M
STRO icon
52
Sutro Biopharma
STRO
$423M
$15.3M 0.54%
70,252
+6,125
+10% +$1.01M
NVCR icon
53
NovoCure
NVCR
$1.81B
$15.2M 0.53%
87,918
-28,927
-25% -$3.96M
GH icon
54
Guardant Health
GH
$21.3B
$15.2M 0.53%
117,852
– –
FATE icon
55
Fate Therapeutics
FATE
$282M
$15.1M 0.53%
166,317
-51,145
-24% -$3.18M
CVS icon
56
CVS Health
CVS
$132B
$15M 0.53%
219,995
-168,268
-43% -$10.9M
TPTX
57
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$14.5M 0.51%
119,324
+113,647
+2,002% +$12.5M
BPMC
58
DELISTED
Blueprint Medicines
BPMC
$13.8M 0.48%
122,699
-47,319
-28% -$4.99M
NVS icon
59
Novartis
NVS
$293B
$13.6M 0.48%
144,525
-7,000
-5% -$612K
IQV icon
60
IQVIA
IQV
$37.8B
$13.6M 0.48%
76,066
-6,200
-8% -$1.04M
RARE icon
61
Ultragenyx Pharmaceutical
RARE
$2.49B
$13.5M 0.47%
97,480
– –
SYNH
62
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$13.3M 0.47%
195,136
+87,135
+81% +$5.43M
SAGE
63
DELISTED
Sage Therapeutics
SAGE
$13.2M 0.46%
152,040
+55,829
+58% +$4.11M
LH icon
64
Labcorp
LH
$24.8B
$13.2M 0.46%
75,198
-6,285
-8% -$1.09M
WELL icon
65
Welltower
WELL
$165B
$13.1M 0.46%
203,083
– –
DGX icon
66
Quest Diagnostics
DGX
$25.5B
$13.1M 0.46%
109,659
– –
IOVA icon
67
Iovance Biotherapeutics
IOVA
$1.94B
$12.6M 0.44%
271,073
– –
APLS
68
DELISTED
Apellis Pharmaceuticals
APLS
$12.4M 0.43%
216,017
– –
TRIL
69
DELISTED
Trillium Therapeutics Inc.
TRIL
$12M 0.42%
817,784
+369,735
+83% +$5.33M
ELV icon
70
Elevance Health
ELV
$81.7B
$11.9M 0.42%
37,133
– –
CRSP icon
71
CRISPR Therapeutics
CRSP
$5.05B
$11.7M 0.41%
76,222
– –
ITCI
72
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$11.6M 0.41%
366,176
+271,938
+289% +$7.15M
TDOC icon
73
Teladoc Health
TDOC
$1.2B
$11.3M 0.4%
+56,520
New +$11.5M
MTD icon
74
Mettler-Toledo International
MTD
$28.7B
$11.2M 0.39%
9,800
– –
JAZZ icon
75
Jazz Pharmaceuticals
JAZZ
$15.9B
$11.1M 0.39%
67,456
– –
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Tekla Capital Management held 216 positions worth $2.85B, up 6.6% from $2.67B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Tekla Capital Management's Q4 2020 filing shows 12 new, 42 increased, 44 reduced and 16 closed positions. Its largest new stake was Teladoc Health: 56,520 shares worth $11.3M. The largest sale was Amgen, an estimated $44.2M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2020 buy was Teladoc Health: 56,520 shares worth $11.3M.
  • Tekla Capital Management added most to Thermo Fisher Scientific in Q4 2020, an estimated $46M increase.
  • Tekla Capital Management's biggest Q4 2020 reduction was Amgen, cutting an estimated $44.2M.
  • Tekla Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $19M.
  • Tekla Capital Management's ten largest holdings make up 28% of its $2.85B portfolio in Q4 2020.
  • Tekla Capital Management opened 12 new positions and closed 16 in Q4 2020.
  • Tekla Capital Management's portfolio value rose 6.6% quarter-over-quarter to $2.85B.

Based on Tekla Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.